Clinical Trial Update: MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial exploring MRD-guided de-intensification of Bendamustine plus Rituximab for indolent non-Hodgkin lymphoma; the study is currently not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING